Noradrenalin Hameln (Noradrenaline Tartrate)

Noradrenaline Tartrate acts as a direct agonist at alpha‑1 and beta‑1 adrenergic receptors. Alpha‑1 activation causes peripheral vasoconstriction, raising systemic vascular resistance, while beta‑1 stimulation increases heart contractility and rate, together improving cardiac output and blood pressure.

The dose of Noradrenalin Hameln is individualized by the treating physician. It is typically administered as a continuous intravenous infusion, with the rate titrated to achieve target blood pressure and perfusion goals based on the patient’s clinical response.

Safety data for Noradrenalin Hameln in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Noradrenalin Hameln, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Noradrenalin Hameln is a first‑line vasopressor because of its potent alpha‑1 mediated vasoconstriction and modest beta‑1 activity, offering rapid blood pressure support with relatively predictable effects. Compared with dopamine, it has less tachyarrhythmic risk, and unlike epinephrine, it provides stronger vasoconstriction with less increase in heart rate.

Noradrenalin Hameln must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. The product should be kept in its original packaging until use, and any unused portion should be discarded according to local regulations.

Noradrenalin Hameln is given by intravenous infusion. It is usually diluted in a compatible carrier solution and administered through a calibrated infusion set, allowing precise titration of the infusion rate under continuous hemodynamic monitoring.

Serious risks include life‑threatening cardiac arrhythmias, severe hypertension, peripheral ischemia leading to tissue necrosis, and extravasation injury if the drug leaks from the vein. Prompt recognition and immediate corrective actions are essential to mitigate these complications.

Noradrenalin Hameln should be avoided in patients with uncorrected pheochromocytoma, severe peripheral vascular disease, or known hypersensitivity to noradrenaline or any formulation component. Use is also contraindicated when adequate volume resuscitation has not been achieved.